| Abstract: | Datamonitor's MedImmune, Inc. - SWOT Analysis company profile is the essential source for top-level company data and information. MedImmune, Inc. - SWOT Analysis examines the company's key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.
Medimmune is a biotechnology company, engaged in the development, manufacture and commercialization of medicines in the areas of infectious diseases, cancer and inflammatory disease. The company's major products include Synagis, FluMist and Ethyol. The company primarily operates in the US. It is headquartered in Gaithersburg, Maryland and employs about 2,400 people. The company recorded revenues of $1,276.8 million during the fiscal year ended December 2006; an increase of 2.6% over 2005. The operating loss of the company was $8.5 million during fiscal year 2006, when compared to the operating loss of $36.7 million in 2005. The net profit was $48.7 million in fiscal year 2006, when compared to the net loss of $16.6 million in 2005.
Scope of the Report
- Provides all the crucial information on MedImmune, Inc. required for business and competitor intelligence needs
- Contains a study of the major internal and external factors affecting MedImmune, Inc. in the form of a SWOT analysis as well as a breakdown and examination of leading product revenue streams of MedImmune, Inc.
-Data is supplemented with details on MedImmune, Inc. history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available statement from MedImmune, Inc.
Reasons to Purchase
- Support sales activities by understanding your customers' businesses better
- Qualify prospective partners and suppliers
- Keep fully up to date on your competitors' business structure, strategy and prospects
- Obtain the most up to date company information available
|
| Brief Excerpt: | ...Medimmune is a biotechnology compan y, engaged in the de velopment, man ufacture and commercialization of medicines in the areas of inf ectious diseases , cancer and inflammator y disease .The compan y's major products include Synagis , FluMist and Eth yol.The compan y pr imarily oper atesin the US . It is headquar tered in Gaithersb urg, Mar yland and emplo ys about 2,400 people .The compan y recorded re venues of $1,276.8 million dur ing the fiscal y ear ended December 2006; an increase of 2.6% o ver 2005. The oper ating loss of the compan y w as $8.5 million dur ing fiscal year 2006, when compared to the oper ating loss of $36.7 million in 2005. The net profit w as $48.7 million in fiscal y ear 2006, when compared to the net loss of $16.6 million in 2005. ...
|
